BrightSpring Health Services reported second-quarter 2026 net revenue of $3.873 billion, a 23.0% increase driven by volume gains and new-market expansion, and raised its full-year guidance. Adjusted EBITDA rose 44.2% to $205.5 million, with margin improving 80 basis points to 5.3%, while adjusted EPS reached $0.45 per diluted share. Pharmacy Solutions revenue grew 22% to $3.407 billion, led by branded limited-distribution drugs and acute infusion, and Provider Services revenue jumped 30% to $466 million, aided by home-health census growth and branch acquisitions. The company now expects full-year 2026 revenue of $15.1 billion to $15.425 billion, representing 17.0% to 19.5% growth, and adjusted EBITDA of $820 million to $845 million, up 32.8% to 36.8% year-over-year. BrightSpring also reported net debt of $1.7 billion as of June 30, 2026, with leverage reduced to 2.15x, and $120 million in share repurchases year-to-date.
BrightSpring Health Services, Inc. Common StockQ2 revenue grew 23% and full-year guidance raised, with adjusted EBITDA up 44.2%.
